Development of Novel Antibiotic Alternatives

a technology of antibiotic alternatives and antibiotics, applied in the direction of antibacterial agents, peptide/protein ingredients, peptide sources, etc., can solve the problems of not being cost-effective to purify this protein, and death of cellular targeted bacteria

Inactive Publication Date: 2008-12-04
IOWA STATE UNIV RES FOUND
View PDF3 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The ion leakage caused by these channels uncouples energy expenditures from growth, causing death in cellular targeted bacteria.
Although colicins have shown potential as alternatives to conventional antibiotics in animal feed, it would not be cost effective to purify this protein from naturally occurring colicin producing E. coli strains, nor to include the levels of these bacteria necessary to obtain an antimicrobial effect in the feed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Development of Novel Antibiotic Alternatives
  • Development of Novel Antibiotic Alternatives
  • Development of Novel Antibiotic Alternatives

Examples

Experimental program
Comparison scheme
Effect test

example 1

Colicin Production, Purification, and Efficacy

Colicin Production and Purification

[0073]Colicin producing E. coli strains, obtained from the National Collection of Type Cultures (Public Health Laboratory Service, London, England), were inoculated into Luria Broth (LB) to a starting OD600˜0.1, and incubated with shaking at 37° C. When the cultures reached an OD600=0.9 colicin production was induced by the addition of 0.2 U Mitomycin C (Sigma) / mL culture. The cell free supernatant was obtained by centrifugation 5.5 h later, and concentrated by ultrafiltration in a stir-cell apparatus (Amicon, Millipore, Bedford, Mass.) across a regenerated cellulose membrane with a 30 kDa cut-off (Millipore). The concentrated sample was then desalted against 10 mM Tris-Cl, pH 8 and purified by ion exchange chromatography. The desalted samples were applied to a column containing Q Sepharose (Amersham Biosciences, Piscataway N.J.), equilibrated with 10 mM Tris-Cl, pH 8.0 (equilibration buffer), and exhau...

example 2

Inhibition of Growth of Escherichia coli 0157:H7 In Vitro

Materials and Methods

Colicin Production and Purification

[0080]Each colicin was produced from a specific colicin-producing E. coli K-12 strain (NC50129-01 containing plasmid pColA-CA31, NC50132-01 containing plasmid pColE1-K53, and NC50145-01 containing plasmid pColN-284) obtained from the National Collection of Type Cultures (Public Health Laboratory Service, London, UK). Cultures were inoculated into Luria-Bertani (LB) broth to an initial optical density of 600 nm (OD600) of approximately 0.1 and incubated in a shaker at 37° C. When the cultures reached OD600=0.9, colicin production was induced by the addition of 0.2 U of mitomycin C per ml of culture (Sigma Chemicals, St. Louis, Mo.). The cell-free supernatant was obtained by centrifugation 5.5 h later and concentrated by ultrafiltration in a stir-cell apparatus (Amicon, Millipore, Bedford, Mass.) across a regenerated cellulose membrane with a 30-kDa cut-off (Millipore). The...

example 3

Recombinant Expression of Colicins

[0092]Yeast expression vectors were constructed and verified by sequencing for Colicin A, B, E1, 1a, and N. Expression and secretion of an active Colicin A by Pichia pastoris were obtained, and confirmed by spot testing of cell-free supernatant of Pichia pastoris expressing Colicin A against E. coli DH5α. In the functional assay (spot testing) 110 μl of cell-free supernatant from transformed P. pastoris showed a clearing of approximately the same size as 1 μg of purified Colicin A from E. coli. Spot 2 showed 1 μl of cell-free supernatant from P. pastoris. Spot 3 showed 5 μl of cell-free supernatant from P. pastoris, and spot 4 showed 10 μl of cell-free supernatant from P. pastoris.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
volumeaaaaaaaaaa
Login to view more

Abstract

The present invention relates to two recombinant colicin expression systems, one utilizing a yeast expression system that produces a protein that is inexpensive to purify, and the other utilizing a plasmid expression system to be used as a probiotic culture. The recombinant colicins provide effective alternatives to conventional antibiotics and may be used to improve the efficiency of pork production, and the safety of its products.

Description

BACKGROUND OF THE INVENTION[0001]It is estimated that over 50% of all economic losses in weaned pigs are due to Escherichia coli infections, causing either diarrhea or edema disease. In addition to the E. coli strains responsible for disease in pigs, other E. coli, as well as Salmonella, strains also colonize the intestinal tract of pigs. Many of these strains are of major concern for human food safety. The U.S. Centers for Disease Control and Prevention (CDC) estimates that in the year 2000 over 1.4 million people suffered and more than 600 died, in this country, from foodborne disease caused by Salmonella and E. coli 0157:H7. The costs attributed to these diseases were approximately $3.1 billion.[0002]The bacterial strains considered primarily responsible for E. coli infections in pigs, F4 (K88) and F18, are not well controlled by traditional prophylactic antibiotic treatments. With worldwide concerns over the use of prophylactic antibiotics in animal agriculture, the development ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/00A61P31/00A61P31/04A61K38/16
CPCA23K1/1631A23K1/184A61K38/164C07K14/195C07K14/245A23K20/147A23K50/30A61P31/00A61P31/04
Inventor STAHL, CHAD H.
Owner IOWA STATE UNIV RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap